SGN-15

SGN-15

A formulation of a monoclonal antibody bound to a cytotoxic antibiotic (BR96-doxorubicin) which made it to Phase-II trials with “encouraging trends” reported for managing lung cancer. Its sponsorship ceased in 2005.